At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities.
Expanding Collaborations in Pharmaceutical Innovation
France’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially established in 2023, to explore broader cooperation prospects in the deep integration of pharmaceutical business innovation.
Vaccine Collaboration and HIV Product Development
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) and SPH have agreed to intensify their collaboration in the vaccine sector, covering product promotion, introduction of innovative products, and policy research. Gilead Sciences Inc., (NASDAQ: GILD) and SPH have partnered to delve deeper into HIV product development, leveraging Gilead’s R&D and manufacturing strengths and SPH’s import distribution expertise to enhance regional coverage of HIV products across China.
Omni-Channel Collaboration and Commercialization of Novel Drugs
Germany’s Bayer (ETR: BAYN) has teamed up with SPH to bolster the high-quality development of novel products through omni-channel strategies, building on previous collaborations to commercialize Bayer’s five brand drugs in China. China’s SciClone Pharmaceuticals Inc., (HKG: 6600) and SPH will integrate SciClone’s novel drug development and commercialization advantages with SPH’s clinical study, import distribution, retail coverage, and innovation value-added services to commercialize SciClone’s in-licensed novel drugs in China.
Ophthalmology and Oncology Focused Partnerships
The partnership with Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) will focus on Ocumension’s seven listed developed products obtained through a closed equity and product deal with US firm Alcon Laboratories Inc. SPH will utilize its extensive distribution network and professional service capabilities to support these programs. Visen Pharmaceuticals, a joint venture between Denmark’s Ascendis Pharma and Chinese investment firm Vivo Capital, has confirmed SPH as its import general agent for lonapegsomatropin, TransCon hGH, a once-weekly long-acting growth hormone under marketing review in China, and its matching autoinjector.
Long-Term Collaborations in Oncology and Beyond
Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc., (HKG: 1530) have agreed to a long-term collaboration with SPH in the oncology field. The list of partners also includes Japan’s Eisai Co., Ltd, (TYO: 4523), Swiss Novartis (NYSE: NVS), and China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235).- Flcube.com
